{"name":"SANOFI AVENTIS US","slug":"sanofi-aventis-us","ticker":"","exchange":"","domain":"sanofiaventisus.com","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"Pharmaceuticals","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2025-01-01","label":"Osteobios first approved","drug":"Osteobios","drugSlug":"calcitonin","type":"approval","sentiment":"positive"},{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-03-23","label":"SARCLISA Phase 3 readout (Plasma Cell Myeloma Recurrent)","drug":"SARCLISA","drugSlug":"isatuximab-irfc","type":"phase3_readout","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-06-30","label":"SARCLISA Phase 3 readout (Plasma Cell Myeloma)","drug":"SARCLISA","drugSlug":"isatuximab-irfc","type":"phase3_readout","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2028-10-01","label":"SARCLISA Phase 2 readout (Newly Diagnosed Multiple Myeloma)","drug":"SARCLISA","drugSlug":"isatuximab-irfc","type":"phase3_readout","sentiment":"neutral"},{"date":"2029-06-01","label":"SARCLISA Phase 3 readout (Multiple Myeloma)","drug":"SARCLISA","drugSlug":"isatuximab-irfc","type":"phase3_readout","sentiment":"neutral"},{"date":"2033-10-21","label":"SARCLISA Phase 3 readout (Plasma Cell Myeloma)","drug":"SARCLISA","drugSlug":"isatuximab-irfc","type":"phase3_readout","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Osteobios","genericName":"CALCITONIN","slug":"calcitonin","indication":"Symptomatic Paget's disease of bone","status":"marketed"}]},{"name":"Infectious Disease","slug":"infectious-disease","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"Rifadin","genericName":"Rifampicin","slug":"rifampicin","indication":"Acute tuberculosis","status":"marketed"}]},{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"cardiovascular","drugs":[{"name":"SARCLISA","genericName":"ISATUXIMAB-IRFC","slug":"isatuximab-irfc","indication":"Multiple myeloma","status":"marketed"}]}],"pipeline":[{"name":"Osteobios","genericName":"CALCITONIN","slug":"calcitonin","phase":"marketed","mechanism":"Calcitonin salmon acts as a calcitonin receptor agonist, primarily affecting bone, with additional effects on the kidneys and gastrointestinal tract.","indications":["Symptomatic Paget's disease of bone","Hypercalcemia","Postmenopausal osteoporosis"],"catalyst":""},{"name":"Rifadin","genericName":"Rifampicin","slug":"rifampicin","phase":"marketed","mechanism":"Solute carrier organic anion transporter family member 1A2, ATP-binding cassette sub-family G member 2, Alpha-synuclein","indications":["Acute tuberculosis","Inactive tuberculosis","Meningococcus carrier","Prevention of Meningococcal Meningitis","Pulmonary tuberculosis"],"catalyst":""},{"name":"SARCLISA","genericName":"ISATUXIMAB-IRFC","slug":"isatuximab-irfc","phase":"marketed","mechanism":"Lymphocyte differentiation antigen CD38","indications":["Multiple myeloma"],"catalyst":""}],"recentEvents":[],"realNews":[],"patents":[],"drugCount":3,"phaseCounts":{"marketed":3},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}